Cardiovascular disease remains the leading cause of death worldwide, and aging is its most powerful risk factor. As blood vessels age, they accumulate senescent cells — cells that have stopped dividing but refuse to die — releasing a cocktail of inflammatory signals that gradually erode arterial flexibility, endothelial function, and heart muscle resilience. Understanding what drives this vascular deterioration is one of the most active areas of cardiovascular biology today.
Fisetin, a naturally occurring flavonoid concentrated in strawberries, apples, and onions, has attracted scientific attention as a senolytic compound — one that selectively clears senescent cells by activating programmed cell-death pathways. A small but growing body of preclinical research now suggests fisetin may have measurable effects on vascular aging markers. This article reviews that evidence honestly, explains the proposed mechanisms in plain terms, and is direct about what remains unknown.
Key Takeaways
- Vascular niches — not just heart muscle — are now recognized as primary drivers of cardiac aging, making vascular senescent cells a logical therapeutic target [4].
- Fisetin acts as a senolytic by suppressing the PI3K-Akt-Bcl-2/Bcl-xL survival pathway, which may selectively clear senescent cells from vascular tissue [2].
- Intermittent fisetin supplementation improved arterial function in aged mice, linked to a reduction in vascular cellular senescence [1].
- Fisetin reversed age-related endothelial dysfunction in animal models, partly by reducing the SASP inflammatory factor CXCL12 produced by senescent endothelial cells [5].
- All cardiovascular evidence for fisetin to date is from animal studies — no human clinical trials have established cardiovascular benefit, and high-dose senolytic protocols have not been validated for safety or efficacy in people.
Why Vascular Aging Is Central to Heart Health
The heart does not age in isolation. Emerging research points to the vascular environment — the network of blood vessels supplying and surrounding the heart — as a central orchestrator of cardiac decline. A 2025 analysis in Circulation Research identified vascular niches as the primary hotspots in cardiac aging, suggesting that deterioration in the vasculature, rather than in heart muscle cells alone, drives much of what we recognize as an aging heart [4].
Vascular senescence — the accumulation of dysfunctional, senescent cells in arterial walls and the endothelium — stiffens vessels, impairs blood-flow regulation, and amplifies local and systemic inflammation. This creates a feedback loop: inflamed, stiff arteries increase the workload on the heart, which in turn accelerates cardiac aging. Targeting vascular senescent cell burden has therefore become a compelling experimental strategy in longevity-oriented cardiovascular research.
How deeply genetics and molecular signaling shape this process is illustrated by progranulin, a growth factor with anti-inflammatory properties. Research published in 2026 found that progranulin deficiency induces premature vascular senescence and dysfunction, producing a phenotype that resembles accelerated arterial aging even in younger animals [6]. Work like this helps establish that cellular senescence is a genuine causal driver of vascular decline — not merely a bystander marker of old age.
Fisetin as a Senolytic: The Proposed Mechanism
Senolytics work by exploiting survival pathways that senescent cells depend on to evade apoptosis — the body’s normal process of programmed cell death. Fisetin appears to act primarily through the PI3K-Akt signaling axis, which in turn regulates the anti-apoptotic proteins Bcl-2 and Bcl-xL. When fisetin suppresses this pathway, senescent cells that had been sheltered from death become vulnerable again, and are selectively cleared without comparable harm to healthy, actively dividing cells.
A 2025 study in Phytotherapy Research specifically examined this mechanism in the context of blood vessel aging, finding that fisetin clears senescent cells in aortic tissue through the PI3K-Akt-Bcl-2/Bcl-xL pathway [2]. The researchers linked this senolytic action to improvements in aortic aging markers in a mouse model. While these findings are preclinical and do not establish human therapeutic benefit, they clarify the molecular logic underlying fisetin’s proposed cardiovascular effects and distinguish it from non-specific antioxidant activity.
Arterial Function: Evidence from Aged Mice
The most directly cardiovascular-relevant preclinical evidence comes from a 2024 study published in Aging Cell, which tested intermittent fisetin supplementation in aged mice. Intermittent dosing was chosen to approximate the ‘hit and run’ senolytic protocol — high doses delivered periodically to clear senescent cells, rather than continuous low-dose supplementation. The study found that this approach improved arterial function in old mice, with the improvements linked to a measurable decrease in cellular senescence within vascular tissue [1].
The distinction between intermittent and continuous dosing matters mechanistically. Unlike an antioxidant taken daily, a senolytic clears a cellular burden; once senescent cells are removed, their inflammatory output diminishes until new senescent cells accumulate over time. The intermittent protocol in this study provided a proof-of-concept that periodic fisetin exposure can modulate the vascular senescent cell load in aging animals. However, the optimal dose, timing, and frequency in humans has not been established, and scaling animal senolytic protocols directly to human use is not supported by clinical evidence.
Endothelial Dysfunction and the SASP Connection
The endothelium — the single-cell lining of every blood vessel — is among the most senescence-sensitive tissues in the cardiovascular system. Endothelial dysfunction, characterized by impaired nitric oxide production and reduced ability to regulate vascular tone, is an early and consistent feature of both cardiovascular aging and disease. Senescent endothelial cells secrete a pro-inflammatory mixture of cytokines, chemokines, and growth factors collectively called the senescence-associated secretory phenotype (SASP), which can perpetuate dysfunction in neighboring healthy cells.
Research published in Aging Cell in 2026 found that senolytic treatment with fisetin reverses age-related endothelial dysfunction in aged mice, and that this reversal was partially mediated by the SASP factor CXCL12 [5]. CXCL12 is a chemokine typically associated with cell migration and inflammation; its elevation in aged vasculature appears to contribute materially to endothelial impairment. By reducing the burden of senescent cells producing CXCL12, fisetin treatment was associated with measurable improvement in endothelial function markers in these animals.
This line of investigation appeared initially in preprint form [3], and the subsequent peer-reviewed publication in 2026 [5] strengthens the signal that CXCL12-mediated SASP is a mechanistically relevant pathway — and that fisetin’s senolytic activity can reduce it in animal models. Whether this translates to meaningful improvement in endothelial function in older humans remains to be tested in adequately powered clinical trials.
Diabetic Vascular Aging: A Higher-Burden Context
Diabetes accelerates vascular senescence well beyond what chronological age alone produces. Chronically elevated blood glucose promotes oxidative stress, advanced glycation end products, and persistent low-grade inflammation — all of which drive endothelial and smooth muscle cells toward a senescent phenotype years or decades earlier than in metabolically healthy individuals.
The 2025 Phytotherapy Research study specifically modeled this accelerated context by studying diabetic aortic aging, and found that fisetin cleared senescent cells through the PI3K-Akt-Bcl-2/Bcl-xL pathway and alleviated aortic aging markers in this mouse model [2]. The high senescent cell burden in diabetes may in theory make senolytic interventions more likely to produce measurable effects — but this reasoning has not been tested in humans. This is not evidence that fisetin is a treatment for diabetic vascular disease. Individuals with diabetes, particularly those on glucose-lowering or anticoagulant medications, should not attempt high-dose fisetin protocols without physician supervision.
Where the Evidence Currently Stands
It is important to be direct about the limits of the current evidence base. Every cardiovascular finding reviewed in this article comes from animal studies — primarily mice. Rodent vascular physiology, lifespan, and senescent cell dynamics differ from humans in important ways, and preclinical findings in senolytics have not always translated to human benefit in other disease areas. The mechanistic picture is coherent and the animal data is encouraging, but it is preclinical evidence, not clinical proof.
No published, adequately powered randomized controlled trial has demonstrated that fisetin supplementation improves arterial stiffness, endothelial function, or cardiovascular event rates in humans. Early human fisetin trials have focused primarily on frailty and inflammation biomarkers — not cardiovascular endpoints. The field is moving, but the human data needed to draw clinical conclusions does not yet exist.
The intermittent high-dose protocols used in animal senolytic studies — often delivering fisetin at doses that, scaled to human body weight, would be very large — have not been established as safe or effective in people. Fisetin is sold as a dietary supplement and is not FDA-approved for any cardiovascular indication. People taking anticoagulants, antiplatelet drugs, or medications metabolized by CYP3A4 liver enzymes should exercise particular caution, as flavonoids can interact with these pathways, and should consult a qualified healthcare provider before use.
🛒 Where to Buy Fisetin
- Life Extension Bio-FisetinLab-tested / studied
capsules, 24 mg per capsule (enhanced-bioavailability liposomal blend) — One of the category’s flagship products; liposomal delivery is designed to improve oral absorption; the lower per-capsule dose requires stacking multiple capsules for research-level senolytic protocols - NOW Foods Fisetin
capsules, 100 mg per capsule — NSF-certified GMP facility; widely available at retail and online; reliable entry-level option for low-dose daily regimens - Double Wood Supplements Fisetin
capsules, 100 mg per capsule (60 count) — USA-manufactured and third-party tested; consistently strong Amazon ratings; popular choice in r/longevity for cost-effective daily use - Swanson Fisetin
capsules, 100 mg per capsule — Established supplement brand with broad distribution; budget-friendly for users wanting a recognizable name at a low cost per dose
As an Amazon Associate we earn from qualifying purchases. Shilajit quality varies widely — always choose a product with a published third-party heavy-metal test (COA) before buying.
A Note on the Evidence
All cardiovascular evidence for fisetin reviewed here comes from animal models; no adequately powered human clinical trials have demonstrated benefit for arterial stiffness, endothelial function, or cardiovascular outcomes. The high intermittent doses used in preclinical senolytic protocols have not been established as safe or effective in people, and fisetin is not FDA-approved for any cardiovascular indication. Individuals taking anticoagulants, antiplatelet drugs, blood-glucose-lowering medications, or CYP3A4-sensitive drugs should consult a qualified healthcare provider before use.
Frequently Asked Questions
What is fisetin and why is it being studied for heart health?
Fisetin is a flavonoid found naturally in strawberries, apples, and onions. It is studied for cardiovascular aging because it acts as a senolytic — a compound that selectively clears senescent cells from tissues. Since vascular niches are now identified as primary hotspots in cardiac aging [4], compounds that reduce the senescent cell burden in blood vessels have attracted significant research interest.
What does 'senolytic' mean and how does fisetin work as one?
A senolytic is a compound that selectively induces programmed cell death in senescent cells — cells that have stopped dividing but resist dying, secreting inflammatory signals in the process. Fisetin achieves this by inhibiting the PI3K-Akt-Bcl-2/Bcl-xL survival pathway, which senescent cells rely on to avoid apoptosis [2]. Healthy, non-senescent cells are less dependent on this pathway and are thus less affected by fisetin’s action.
Has fisetin been shown to improve arterial function?
In aged mice, yes. A 2024 study found that intermittent fisetin supplementation improved arterial function in old mice, with the improvement linked to a measurable reduction in cellular senescence within the vasculature [1]. This is preclinical animal evidence only — it does not establish that the same effect occurs in humans.
What is endothelial dysfunction, and does fisetin affect it?
Endothelial dysfunction refers to impaired performance of the cell lining inside blood vessels — including reduced nitric oxide production and compromised regulation of vascular tone — and is an early marker of cardiovascular risk. In aged mice, senolytic treatment with fisetin reversed age-related endothelial dysfunction, partially through reductions in the SASP factor CXCL12 secreted by senescent endothelial cells [5]. No human data currently supports this finding.
Is fisetin particularly relevant to diabetic vascular aging?
Preclinical research suggests it may be worth investigating in that context. A 2025 study found that fisetin cleared senescent cells through the PI3K-Akt-Bcl-2/Bcl-xL pathway and alleviated markers of aortic aging in a diabetic mouse model [2]. Diabetes accelerates vascular senescence significantly, which may in theory increase the potential impact of senolytic treatment — but this has not been tested in people, and individuals on diabetes or cardiovascular medications should consult their physician before considering any fisetin protocol.
Is fisetin safe to use for cardiovascular health?
Fisetin is sold as a dietary supplement and is generally considered low risk at amounts found in food. However, the intermittent high-dose senolytic protocols used in preclinical cardiovascular studies have not been established as safe or effective in humans, and fisetin is not FDA-approved for any heart-related indication. People taking anticoagulants, antiplatelet medications, or drugs processed by CYP3A4 liver enzymes should discuss use with a physician, as flavonoids can influence these pathways. This article is informational and does not constitute medical advice.
References
- Mahoney SA et al. Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence. Aging cell (2024). PMID 38062873
- Ji XM et al. Fisetin Clears Senescent Cells Through the Pi3k-Akt-Bcl-2/Bcl-xl Pathway to Alleviate Diabetic Aortic Aging. Phytotherapy research : PTR (2025). PMID 40259678
- Mahoney SA et al. Senolytic treatment with fisetin reverses age-related endothelial dysfunction partially mediated by SASP factor CXCL12. bioRxiv : the preprint server for biology (2025). PMID 40894771
- Rodriguez Morales D et al. Vascular Niches Are the Primary Hotspots in Cardiac Aging. Circulation research (2025). PMID 41090219
- Mahoney SA et al. Senolytic Treatment With Fisetin Reverses Age-Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12. Aging cell (2026). PMID 42021544
- Luvizotto RAM et al. Progranulin deficiency induces premature vascular senescence and dysfunction. American journal of physiology. Heart and circulatory physiology (2026). PMID 42233590
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
